Transforming genetic discoveries into groundbreaking treatments
We are accelerating the journey from genetic discovery to groundbreaking therapies in neurology, autoimmune diseases, and inflammatory skin conditions.
Our R&D efforts are operated by a team of international experts in genomics, bioinformatics, neurology, inflammation and immunology
– augmented by a world-class network of leading scientists and research institutions across the United States and Europe.
The Pulse
-
The European Medicines Agency (EMA) authorises initiation of a Phase IIa study evaluating AT-001 in patients diagnosed with Alzheimer’s disease EMA grants Orphan Drug Designation (ODD) to AT-001 for hereditary cystatin C amyloid angiopathy (HCCAA), a rare familial dementia REYKJAVIK, ICELAND – November 3, 2025 – Arctic Therapeutics (ATx), an…
Events
No upcoming events.